Armata Pharmaceuticals, Inc.
ARMP
$5.41
-$0.41-7.05%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.72% | 60.69% | -12.15% | -61.02% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.72% | 60.69% | -12.15% | -61.02% | -- |
| Cost of Revenue | 18.64% | 12.56% | -3,884.31% | -38.60% | -24.55% |
| Gross Profit | -20.14% | -7.78% | 154.65% | 28.36% | 50.15% |
| SG&A Expenses | 99.92% | 6.46% | -2.53% | -4.10% | -23.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.26% | 10.27% | -19.35% | -29.81% | -24.35% |
| Operating Income | -50.67% | -7.25% | 20.19% | 20.30% | 42.55% |
| Income Before Tax | 554.99% | -1,666.13% | -4,880.69% | -386.68% | -281.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 554.99% | -1,666.13% | -4,880.69% | -386.68% | -281.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 554.99% | -1,666.13% | -4,880.69% | -386.68% | -281.34% |
| EBIT | -50.67% | -7.25% | 20.19% | 20.30% | 42.55% |
| EBITDA | -50.06% | -6.58% | 21.32% | 21.57% | 44.15% |
| EPS Basic | 548.16% | -1,649.31% | -4,855.63% | -386.01% | -281.17% |
| Normalized Basic EPS | -57.61% | -20.57% | 4.65% | 2.95% | 26.90% |
| EPS Diluted | 39.58% | -1,501.62% | -553.20% | -386.01% | -81.97% |
| Normalized Diluted EPS | 6.64% | -98.22% | -55.73% | 2.95% | -17.79% |
| Average Basic Shares Outstanding | 1.53% | 0.95% | 0.47% | 0.13% | 0.11% |
| Average Diluted Shares Outstanding | 71.42% | -38.58% | -38.47% | 0.13% | -37.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |